Experience with isavuconazole in the treatment of mucormycosis and breakthrough fungal infections
Revista Iberoamericana de Micología · 2025
DOI: 10.1016/j.riam.2025.01.005 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Revista Iberoamericana de Micología, 2025. Verfasst von Carolina Garcia-Vidal und 5 weiteren Autor:innen. Beteiligte Einrichtung: Infectious Disease Department, Hospital Clinic of Barcelona-IDIBAPS, University of Barcelona, Barcelona, Spain; Facultat de Medicina i Ciències de la…. Hauptthemen laut MEDLINE: Mucormycosis, Triazoles, Pyridines, Nitriles. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 20 Literaturangaben. Gefördert von: AGAUR, Pfizer, Carlos III Health Institute.
Abstract (Originalsprache)
Isavuconazole, a triazole-class antifungal, is effective and safe for both primary treatment and salvage therapy in a variety of fungal infections. This article reviews recent knowledge on the role of this antifungal in the treatment of mucormycosis and breakthrough invasive fungal infections (bIFI) during antifungal therapy. Isavuconazole has demonstrated favorable clinical outcomes and a good safety profile in various patient populations with mucormycosis, including those with comorbidities such as diabetes mellitus or severe immunosuppression. Particularly noteworthy is the fact that drug interactions in patients with mucormycosis, where a solid organ transplant was a predisposing factor, have been effectively managed. In the treatment of bIFIs, the use of isavuconazole requires a thoughtful reflection about the fungal species involved and their susceptibility profiles. This is highly dependent on the antifungal agent administered before the onset of bIFI. Early diagnosis and appropriate antifungal therapy are essential to improve outcomes in patients with mucormycosis and bIFIs. Isavuconazole represents a valuable option for managing these complex infections.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Infectious Disease Department, Hospital Clinic of Barcelona-IDIBAPS, University of Barcelona, Barcelona, Spain; Facultat de Medicina i Ciències de la Salut, Universitat de Barcelona (UB), Spain. Electronic address: cgar…
- Infectious Disease Department, Hospital Clinic of Barcelona-IDIBAPS, University of Barcelona, Barcelona, Spain; Facultat de Medicina i Ciències de la Salut, Universitat de Barcelona (UB), Spain.
- Infectious Disease Department, Hospital Clinic of Barcelona-IDIBAPS, University of Barcelona, Barcelona, Spain.
Förderung
- AGAUR
- Pfizer
- Carlos III Health Institute
- European Commission
Zitieren
APA
Garcia-Vidal, C., Gallardo-Pizarro, A., Aiello, T. F., Martinez-Urrea, A., Teijon-Lumbreras, C., & Monzo-Gallo, P. (2025). Experience with isavuconazole in the treatment of mucormycosis and breakthrough fungal infections. Revista Iberoamericana de Micología. https://doi.org/10.1016/j.riam.2025.01.005
Vancouver
Garcia-Vidal C, Gallardo-Pizarro A, Aiello TF, Martinez-Urrea A, Teijon-Lumbreras C, Monzo-Gallo P. Experience with isavuconazole in the treatment of mucormycosis and breakthrough fungal infections. Revista Iberoamericana de Micología. 2025. doi:10.1016/j.riam.2025.01.005
BibTeX
@article{GarciaVidal2025,
author = {Garcia-Vidal, Carolina and Gallardo-Pizarro, Antonio and Aiello, Tommaso Francesco and Martinez-Urrea, Ana and Teijon-Lumbreras, Christian and Monzo-Gallo, Patricia},
title = {Experience with isavuconazole in the treatment of mucormycosis and breakthrough fungal infections},
journal = {Revista Iberoamericana de Micología},
year = {2025},
doi = {10.1016/j.riam.2025.01.005}
}
EUVIMED